entertainment -WSS

entertainment

author：focus 2025-08-23 08:56:24 - browse：3

a person wearing blue dress conducts a finger prick test on another person in a home setting — coverage from STAT — Adobe

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

A systematic review by the Peterson Health Technology Institute found, though, that digital tools used to manage diabetes with the help of finger-stick blood glucose readings don’t result in clinically meaningful improvements over standard care. As a result, they don’t reduce health care spending — they drive it up.

“Most of the solutions in this category do not deliver clinical benefits that justify their cost,” Caroline Pearson, executive director of the institute, told STAT. Despite finding that some populations may benefit, the report concludes that current evidence doesn’t support broader adoption for most products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： As biotech industry slumps, bioscience job market is upside down

WSS

With clinical trial data readouts, here's how to spot spin

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Akili changes sales model for its ADHD video game treatment

Fed up with FDA, ALS advocates consider a take

What don’t we know about an Alzheimer’s drug side effect?

Organ aging and disease risk measured by new blood test

hotspot

entertainment

focus

Medical leaders decry Supreme Court decision on affirmative action

David Liu startup to focus on CRISPR delivery

State Dept. review finds Biden bears some blame for Afghanistan failures

What to do when lifesaving products contribute to climate change

Hepatitis C has a cure — but many Americans still lack access to it

Pediatric cancer treatments threatened by a new FDA policy

Bright Health sells Medicare Advantage business to Molina

FDA panel to weigh safety of artificial wombs for preterm births

Psychedelics group wrestles with new pharma identity

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

knowledge

Grad students accuse University of California of wage theft

The EPA's new lead rule: How one expert crunched the numbers

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Assistant physicians can help address the primary care shortage

Senate bill would ban some hospital facility fees

Diagnostic tests are hitting their mathematical limits

explore

focus

hotspot

hotspot